Prot #MK-3475-061-02: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and F

Project: Research project

StatusActive
Effective start/end date10/29/1510/29/21

Funding

  • Merck Sharp & Dohme Corp. (Prot #MK-3475-061-02)